North America Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market By Medication (Stimulants-Amphetamines, Non-Stimulants-Bupropion), Psychotherapy (Behavior Therapy, Cognitive Behavioral Therapy), And Education Or Training (Parent Management Training, Family Therapy) – Market Analysis, Size, Geographic Countries Analysis, Competitive Strategies Analysis And Forecasts 2018-2023

North America Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market By Medication (Stimulants-Amphetamines, Non-Stimulants-Bupropion), Psychotherapy (Behavior Therapy, Cognitive Behavioral Therapy), And Education Or Training (Parent Management Training, Family Therapy) – Market Analysis, Size, Geographic Countries Analysis, Competitive Strategies Analysis And Forecasts 2018-2023

ID: 305 | Pages: 145 | October 2018 | Region: North America


North America attention deficit hyperactivity disorder (ADHD) therapeutics market is expected to reach USD 5.15 billion by 2023 from USD 3.64 billion in 2018, growing at a CAGR of 7.20% during the forecast period 2018-2023. Attention deficit hyperactivity disorder (ADHD), is one of the most common neurological/psychiatric disorders among children and adolescents. ADHD is commonly observed in children (<12 years age) as compared to adolescents. ADHD is also described as hyperkinetic disorder/ attention deficit disorder or neuropsychiatric disorder.

The exact cause for the ADHD is not clear but, expected to be resulted due to genetic factors and environmental influences. ADHD results in improper functioning of nervous system that led to attention deficit and hyperactivity/impulsiveness condition. ADHD is characterized by certain symptoms include easy distraction & striving to maintain focus on one task, unable to remember things, impatience, and being continuously in motion, among others. The symptoms of attention deficit hyperactivity disorder (ADHD) are controlled by different modalities such as medication (stimulants-amphetamines; non-stimulants-atomoxetine), psychotherapy (behavior therapy, cognitive behavioral therapy), and education/training (parent management training, family training).

Availability of good healthcare infrastructure, presence of ongoing clinical trials, early approval of therapeutics in the U.S., increasing number of learning disability patients, growing adoption for ADHD therapeutics, existence of insurance policies for brain monitoring technologies, and government support for the technological advancements in neurosciences are driving the growth of attention deficit hyperactivity disorder therapeutics market in North America.

However, stringent government regulations for the approval of neurological therapeutics and cost pertaining to the ADHD medication are restraining the growth of attention deficit hyperactivity disorder therapeutics market in North America. North America attention deficit hyperactivity disorder (ADHD) therapeutics market is segmented based on medication, psychotherapy, and education or training. Medication involves stimulants and non-stimulants. Medication by stimulants comprises of amphetamines, methylphenidate, dextroamphetamine, and dexmethylphenidate, whereas medication by non-stimulants comprises of atomoxetine, bupropion, and guanfacine. Psychotherapy involves behavior therapy, cognitive behavioral therapy, interpersonal psychotherapy, and family therapy. Education or training involves parent management training, social skills training, and school-based interventions. On the basis of geographical areas, North America attention deficit hyperactivity disorder (ADHD) therapeutics market is segmented as U.S., and Canada. U.S., accounted for larger share of the North America attention deficit hyperactivity disorder (ADHD) therapeutics market in 2018, whereas Canada is estimated to grow at a higher CAGR during the forecast period 2018-2023.

The key players in attention deficit hyperactivity disorder (ADHD) therapeutics market such as, Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.), and Curemark, LLC. (U.S.).

  1. Introduction

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                          

                1.4 General Study Assumptions                                

  1. Research Methodology

                2.1 Introduction                                               

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                           

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                      

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

  1. Overview

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                                              

  1. Market Segmentation

                5.1 Introduction                                               

                5.2 Treatment By Medication                                    

                                5.2.1 Introduction                           

                                5.2.2 Stimulants                               

                                                5.2.2.1 Introduction       

                                                5.2.2.2 Amphetamines 

                                                5.2.2.3 Methylphenidate             

                                                5.2.2.4 Dextroamphetamine      

                                                5.2.2.5 Dexmethylphenidate     

                                5.2.3 Non-Stimulants                     

                                                5.2.3.1 Introduction       

                                                5.2.3.2 Atomoxetine      

                                                5.2.3.3 Bupropion           

                                                5.2.3.4 Guanfacine         

                5.3 Treatment By Psychotherapy                                             

                                5.3.1 Introduction                           

                                5.3.2 Behavior Therapy                 

                                5.3.3 Cognitive Behavioral Therapy                         

                                5.3.4 Interpersonal Psychotherapy                         

                                5.3.5 Family Therapy                      

                5.4 Treatment By Education or Training                                 

                                5.3.1 Introduction                           

                                5.3.2 Parent Management Training                         

                                5.3.3 Social Skills Training                             

                                5.3.4 School-Based Interventions                            

  1. Geographical Analysis

                                6.1 Introduction                               

                                6.2 United States                            

                                6.3 Canada                         

  1. Strategic Analysis

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                       

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services                              

                                7.2.5 Competitive Rivalry within the Industry                     

  1. Market Leaders' Analysis

                8.1 Shire plc (Ireland)                                    

                                8.1.1 Overview                 

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                             

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Neos Therapeutics, Inc. (U.S.)                                            

                8.3 Eli Lilly and Company (U.S.)                                  

                8.4 Pfizer Inc. (U.S.)                                       

                8.5 Alcobra Ltd. (Israel)                                 

                8.6 Supernus Pharmaceuticals, Inc. (U.S.)                                            

                8.7 Noven Pharmaceuticals, Inc. (U.S.)                                  

                8.8 Novartis AG (Switzerland)                                    

                8.9 Johnson & Johnson (U.S.)                                    

                8.10 Curemark, LLC., (U.S.)                                         

  1. Competitive Landscape

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                       

                9.3 Agreements, collaborations and Joint Ventures                                         

                9.4 New Product Launches                                         

  1. Expert Opinions

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

     Appendix                                                          

a) List of Tables

b) List of Figures

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. North America Attention-Deficit Hyperactivity Disorder Therapeutics Market By Region, From 2018-2023 (USD Billion)
  2. North America Attention-Deficit Hyperactivity Disorder Therapeutics Market By Medication, From 2018-2023 (USD Billion)
  3. North America Stimulants Market By Region, From 2018-2023 (USD Billion)
  4. North America Non-Stimulants Market By Region, From 2018-2023 (USD Billion)
  5. North America Attention-Deficit Hyperactivity Disorder Therapeutics Market By Psychotherapy, From 2018-2023 (USD Billion)
  6. North America Behavior Therapy ADHD Therapeutics Market By Region, From 2018-2023 (USD Billion)
  7. North America Cognitive Behavioral Therapy ADHD Therapeutics Market By Region, From 2018-2023 (USD Billion)
  8. North America Interpersonal Psychotherapy ADHD Therapeutics Market By Region, From 2018-2023 (USD Billion)
  9. North America Family Therapy ADHD Therapeutics Market By Region, From 2018-2023 (USD Billion)
  10. North America Attention-Deficit Hyperactivity Disorder Therapeutics Market By Education or Training, From 2018-2023 (USD Billion)
  11. North America Parent Management Training ADHD Therapeutics Market By Region, From 2018-2023 (USD Billion)
  12. North America Social Skills Training ADHD Therapeutics Market By Region, From 2018-2023 (USD Billion)
  13. North America School-based Interventions ADHD Therapeutics Market By Region, From 2018-2023 (USD Billion)
  14. United States Attention-Deficit Hyperactivity Disorder Therapeutics Market By Medication, From 2018-2023 (USD Billion)
  15. United States Attention-Deficit Hyperactivity Disorder Therapeutics Market By Psychotherapy, From 2018-2023 (USD Billion)
  16. United States Attention-Deficit Hyperactivity Disorder Therapeutics Market By Education or Training, From 2018-2023 (USD Billion)
  17. Canada Attention-Deficit Hyperactivity Disorder Therapeutics Market By Medication, From 2018-2023 (USD Billion)
  18. Canada Attention-Deficit Hyperactivity Disorder Therapeutics Market By Psychotherapy, From 2018-2023 (USD Billion)
  19. Canada Attention-Deficit Hyperactivity Disorder Therapeutics Market By Education or Training, From 2018-2023 (USD Billion)
  20. North America Stimulants ADHD Therapeutics Market By Type, From 2018-2023 (USD Billion)
  21. North America Amphetamines Market By Region, From 2018-2023 (USD Billion)
  22. North America Methylphenidate Market By Region, From 2018-2023 (USD Billion)
  23. North America Dextroamphetamine Market By Region, From 2018-2023 (USD Billion)
  24. North America Dexmethylphenidate Market By Region, From 2018-2023 (USD Billion)
  25. United States Stimulants ADHD Therapeutics Market By Type, From 2018-2023 (USD Billion)
  26. Canada Stimulants ADHD Therapeutics Market By Type, From 2018-2023 (USD Billion)
  27. North America Non-Stimulants ADHD Therapeutics Market By Type, From 2018-2023 (USD Billion)
  28. North America Atomoxetine Market By Region, From 2018-2023 (USD Billion)
  29. North America Bupropion Market By Region, From 2018-2023 (USD Billion)
  30. North America Guanfacine Market By Region, From 2018-2023 (USD Billion)
  31. United States Non-Stimulants ADHD Therapeutics Market By Type, From 2018-2023 (USD Billion)
  32. Canada Non-Stimulants ADHD Therapeutics Market By Type, From 2018-2023 (USD Billion)
Middle East And Africa Angina Pectoris Drugs Market By Therapeutic Class ( Beta Blockers, Calcium Antagonists, Anticoagulants, Anti-platelets And Others) And By Region - Global Industry Analysis, Size, Share, Growth...
Asia Pacific Angina Pectoris Drugs Market By Therapeutic Class (beta Blockers, Calcium Antagonists, Anticoagulants, Anti-platelets And Others) And By Region - Global Industry Analysis, Size, Share, Growth, Trends, A...
Europe Angina Pectoris Drugs Market By Therapeutic Class ( Beta Blockers, Calcium Antagonists, Anticoagulants, Anti-platelets And Others) And By Region - Global Industry Analysis, Size, Share, Growth, Trends, And Fo...
North America Angina Pectoris Drugs Market By Therapeutic Class (beta Blockers, Calcium Antagonists, Anticoagulants, Anti-platelets And Others) And By Region - Global Industry Analysis, Size, Share, Growth, Trends, ...
Angina Pectoris Drugs Market By Therapeutic Class (beta Blockers, Calcium Antagonists, Anticoagulants, Anti-platelets And Others) And By Region - Global Industry Analysis, Size, Share, Growth, Trends, And Forecasts ...
Middle East And Africa Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) A...
Latin America Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) And By Reg...
Asia Pacific Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) And By Regi...
Europe Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) And By Region - I...
North America Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) And By Reg...
Schizophrenia Drugs Agents Market By Therapeutic Class ( Second Generation Anti-psychotics, Third Generation Anti-psychotics And Others) , By Treatment ( Oral And Injectable Anti-psychotics) And By Region - Industry...
Pharmaceutical Gelatin Market By Function (stabilizers, Thickeners, Gelling Agents And Others) , By Source( Pig Skin, Bovine Hides, Bones And Others), By Application ( Hard Capsules, Soft Capsules, Microencapsulatio...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.